Imuldosa

Ustekinumab, the active ingredient in Imuldosa, is a IL-12/23 inhibitor presented as a sterile solution for intravenous use. It modulates immune activity and is indicated for the treatment of plaque psoriasis, psoriatic arthritis, and Crohn's disease in adult patients.

GNH USA supplies Imuldosa as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and clinics worldwide. The company adheres to stringent quality standards and provides reliable cold‑chain logistics for biologic products.

Imuldosa (ustekinumab) targets the interleukin‑12 and interleukin‑23 pathways, which are central to several inflammatory disorders.

- Plaque psoriasis: reduces skin plaque formation and improves disease severity. - Psoriatic arthritis: alleviates joint pain, swelling, and structural damage. - Crohn's disease: induces clinical remission and promotes mucosal healing.

Ustekinumab may be associated with a range of adverse reactions, which are generally categorized by frequency and severity.

Common Side Effects: - Upper respiratory tract infection: mild symptoms such as sore throat or nasal congestion. - Headache: transient and usually mild. - Fatigue: general tiredness without specific cause. - Injection site reaction: redness or swelling at the infusion site.

Serious or Rare Side Effects: - Serious infections: including tuberculosis and opportunistic pathogens. - Malignancies: rare cases of lymphoma or skin cancer. - Hypersensitivity reactions: anaphylaxis or severe rash. - Cardiovascular events: rare cases of myocardial infarction or stroke.

Before initiating Imuldosa, several precautionary measures should be considered to ensure patient safety.

- Screen for latent infections: test for tuberculosis and hepatitis before therapy. - Monitor for active infections: postpone dosing if serious infection is present. - Evaluate malignancy risk: avoid use in patients with a history of malignancy unless benefits outweigh risks. - Pregnancy and lactation: use only if potential benefit justifies potential risk, as safety data are limited. - Vaccinations: administer required non‑live vaccines prior to treatment; avoid live vaccines during therapy. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Ustekinumab can interact with other medicines, affecting efficacy or safety.

Major Interactions (Avoid): - Live vaccines: concurrent use may cause uncontrolled infection. - Other biologic immunosuppressants: combined therapy can markedly increase infection risk.

Moderate Interactions (Monitor Closely): - Systemic corticosteroids: may enhance immunosuppression, requiring infection monitoring. - Antifungal agents (e.g., azoles): may affect immune response, monitor for signs of infection. - Cytochrome P450 substrates: ustekinumab has minimal effect, but monitor drugs with narrow therapeutic index.